Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
4.
Eur J Surg Oncol ; 46(2): 263-271, 2020 02.
Article in English | MEDLINE | ID: mdl-31594672

ABSTRACT

INTRODUCTION: Sentinel lymph node (SLN) biopsy is useful for the prognostic stratification of patients with thick melanoma. Identifying which variables are associated with SLN involvement and establishing risk in different subgroups of patients could be useful for guiding the indication of SLN biopsy. The value of complete lymph node dissection (CLND) in patients with a positive SLN biopsy is currently under debate. MATERIALS AND METHODS: To identify factors associated with SLN involvement in thick melanoma we performed a multicentric retrospective cohort study involving 660 patients with thick melanoma who had undergone SLN biopsy. To analyze the role of CLND in thick melanoma patients with a positive SLN biopsy, we built a multivariate Cox proportional hazards model for melanoma-specific survival (MSS) and disease-free survival (DFS) and compared 217 patients who had undergone CLND with 44 who had not. RESULTS: The logistic regression analysis showed that age, histologic subtype, ulceration, microscopic satellitosis, and lymphovascular invasion were associated with nodal disease. The CHAID (Chi-squared Automatic Interaction Detection) decision tree showed ulceration to be the most important predictor of lymphatic involvement. For nonulcerated melanomas, the histologic subtype lentigo maligna melanoma was associated with a low rate of SLN involvement (4.3%). No significant differences were observed for DFS and MSS between the CLND performed and not-performed groups. Nodal status on CLND was associated with differences in DFS and MSS rates. CONCLUSION: We identified subgroups of thick melanoma patients with a low likelihood of SLN involvement. CLND does not offer survival benefit, but provides prognostic information.


Subject(s)
Lymph Node Excision , Melanoma/surgery , Sentinel Lymph Node/pathology , Aged , Female , Humans , Logistic Models , Lymphatic Metastasis , Male , Melanoma/mortality , Melanoma/pathology , Middle Aged , Prognosis , Retrospective Studies , Sentinel Lymph Node Biopsy
5.
Appl Immunohistochem Mol Morphol ; 26(6): 411-419, 2018 07.
Article in English | MEDLINE | ID: mdl-29994799

ABSTRACT

High-endothelial venules are a common feature of 3 types of cutaneous pseudolymphomas: pretibial lymphoplasmacytic plaque (PLP) of children, acral pseudolymphomatous angiokeratoma of children (APACHE), and T-cell rich angiomatoid polypoid pseudolymphoma (TRAPP). In addition, primary cutaneous angioplasmacellular hyperplasia (PCAH) overlaps with these other 3 conditions. We intend to study the expression of peripheral node addressins in PLP, APACHE, TRAPP, and PCAH. We studied 1 case of PLP, 2 cases of APACHE, 2 cases of TRAPP, and 2 cases of PCAH. Immunostainings for MECA-79 and WT-1 were obtained in all cases. All cases showed a dense lymphohistiocytic dermal inflammatory infiltrate with abundant plasma cells. In addition, HEV were prominent in all cases. Cases of PLP, APACHE, and TRAPP expressed MECA-1. Cases of PCAH did not express MECA-1. Although PLP, APACHE, and TRAPP seem to fall under the same morphologic spectrum with different clinical representations, PCAH seems to be a different entity, with histopathologic peculiarities and a different immunophenotype.


Subject(s)
Angiokeratoma/diagnosis , Immunoglobulins/metabolism , Lymph Nodes/metabolism , Mucoproteins/metabolism , Plasma Cells/pathology , Pseudolymphoma/diagnosis , Skin/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Cell Adhesion Molecules , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Hyperplasia , Immunohistochemistry , Male , Middle Aged , Young Adult
6.
Am J Dermatopathol ; 40(7): 479-485, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29924747

ABSTRACT

Sebaceous neoplasms with an organoid pattern (rippled, labyrinthine/sinusoidal, carcinoid-like, and petaloid) are rare. Previous studies suggested that the above patterns likely represent variations along a morphological continuum. The objectives of this study were to (1) validate this proposition by studying a large number of cases, (2) determine whether there are specific associations with clinical features, (3) establish their frequency, and (4) determine whether they have any association with Muir-Torre syndrome. Fifty-seven sebaceous neoplasms (54 sebaceomas and 3 sebaceous carcinomas) with organoid growth patterns were studied. These occurred in 36 men and 18 women (sex unknown in 3), with ages at diagnosis ranging from 22 to 89 years (mean, 63 years). All patients presented with a solitary nodule (mean size, 11 mm) on the head and neck area. Of the 57 tumors, 24 manifested a single growth pattern, 23 had a combination of 2 patterns, and 10 a combination of 3 patterns, indicating that these patterns are part of a morphological continuum of changes. The carcinoid-like pattern was the most frequent in the "monopatterned" neoplasms (13 cases), whereas the labyrinthine/sinusoidal pattern comprised most of the "polypatterned" lesions, in which various combinations occurred. Immunohistochemically, mismatch repair protein deficiency was detected in 3 of the 22 cases studied, whereas 5 of the 33 patients with available follow-up had an internal malignancy/premalignancy. In conclusion, sebaceous neoplasms with organoid growth patterns are predominantly sebaceomas having a predilection for the scalp, occurring as solitary lesions in elderly patients (male to female ratio of 2:1). Such patterns are expected to be found in a quarter of sebaceomas. In most cases, more than one of the organoid patterns is present. These lesions do not appear to be associated with internal malignancy or mismatch repair deficiency in most cases. However, confirmation of the absence of any significant association with Muir-Torre syndrome syndrome will require genetic studies.


Subject(s)
Sebaceous Gland Neoplasms/pathology , Adult , Aged , Aged, 80 and over , DNA Mismatch Repair/genetics , Female , Humans , Male , Middle Aged , Muir-Torre Syndrome/complications , Sebaceous Gland Neoplasms/etiology , Young Adult
8.
Int J Cancer ; 142(3): 641-648, 2018 02 01.
Article in English | MEDLINE | ID: mdl-28960289

ABSTRACT

The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow-up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI) 0.61-0.90); p = 0.002] and OS (AHR, 0.75; 95% CI, 0.60-0.94; p = 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65-1.08; p = 0.165). SLN-negative patients had better 5- and 10-year MSS compared with SLN-positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p = 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.


Subject(s)
Lymph Nodes/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Aged , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Propensity Score , Retrospective Studies , Sentinel Lymph Node Biopsy , Survival Analysis
9.
Am J Dermatopathol ; 39(2): e29-e33, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28134738

ABSTRACT

Leishmanides have been rarely reported in the literature. In this study, the authors present a case of a 50-year-old HIV-positive man who developed a generalized cutaneous eruption of papules and plaques in which no microorganism was demonstrated by culture, microscopical examination, immunohistochemistry, or polymerase chain reaction. The patient was eventually diagnosed with laryngeal leishmaniasis, and when treated, the cutaneous lesions greatly improved.


Subject(s)
Immunocompromised Host , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/pathology , HIV Infections/complications , Humans , Laryngeal Diseases/immunology , Laryngeal Diseases/microbiology , Male , Middle Aged
10.
Am J Dermatopathol ; 34(5): 506-10, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22505039

ABSTRACT

BACKGROUND: About 10% of patients with Merkel cell carcinoma (MCC) suffer from an associated squamous cell carcinoma (SCC). In European patients, Merkel cell polyomavirus (MCPyV) is detectable in 60%-88% of the MCC tumors. In combined lesions, MCPyV was not detectable so far. METHODS: We investigated 2 combined tumors of MCC and SCC for the presence of MCPyV and human papillomavirus (HPV) by polymerase chain reaction and immunohistochemistry. RESULTS: In both lesions, MCPyV DNA was found, and in 1 case, HPV DNA was also detected. This is the first report of a coinfection with HPV and MCPyV in combined MCC-SCC tumors. CONCLUSIONS: The results underline the hypothesis of co-cancerogenesis of 2 oncogenic viruses in nonmelanoma skin cancer. Technical reasons and a low viral copy number of MCPyV hampering immunohistochemical detection may be responsible for the negative results in the literature.


Subject(s)
Carcinoma, Merkel Cell/virology , Carcinoma, Squamous Cell/virology , Immunocompetence , Merkel cell polyomavirus/isolation & purification , Neoplasms, Complex and Mixed , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Polyomavirus Infections/virology , Skin Neoplasms/virology , Tumor Virus Infections/virology , Aged , Aged, 80 and over , Biopsy , Capsid Proteins/analysis , Carcinoma, Merkel Cell/immunology , Carcinoma, Merkel Cell/pathology , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/pathology , DNA, Viral/analysis , Female , Germany , Humans , Immunohistochemistry , Male , Merkel cell polyomavirus/chemistry , Merkel cell polyomavirus/genetics , Oncogene Proteins, Viral/analysis , Papillomaviridae/chemistry , Papillomaviridae/genetics , Papillomavirus Infections/immunology , Polymerase Chain Reaction , Polyomavirus Infections/immunology , Predictive Value of Tests , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Switzerland , Tumor Virus Infections/immunology
11.
Muscle Nerve ; 43(2): 268-73, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21254094

ABSTRACT

Proteolysis in skeletal muscle is mainly carried out by the activity of the ubiquitin-dependent proteolytic system. For the study of protein degradation through the ubiquitin-proteasome pathway, we used a model of hyperthermia in murine myotubes. In C2C12 cells, hyperthermia (41°C) induced a significant increase in both the rate of protein synthesis (18%) and degradation (51%). Interestingly, the addition of the ß(2) -adrenoceptor agonist formoterol resulted in a significant decrease in protein degradation (21%) without affecting protein synthesis. The decrease in proteolytic rate was associated with decreases in gene expression of the different components of the ubiquitin-dependent proteolytic system. The effects of the ß(2) -agonist on protein degradation were dependent exclusively on cAMP formation, because inhibition of adenylyl cyclase completely abolished the effects of formoterol on protein degradation. It can be concluded that hyperthermia is a suitable model for studying the anti-proteolytic potential of drugs used in the treatment of muscle wasting.


Subject(s)
Adrenergic beta-2 Receptor Agonists/pharmacology , Ethanolamines/pharmacology , Hyperthermia, Induced , Muscle Fibers, Skeletal/drug effects , Proteasome Endopeptidase Complex/metabolism , Ubiquitins/metabolism , Analysis of Variance , Animals , Cell Line, Transformed , Cyclic AMP/metabolism , DDT/analogs & derivatives , DDT/pharmacology , Formoterol Fumarate , Gene Expression Regulation/drug effects , Gene Expression Regulation/radiation effects , Immunosuppressive Agents/pharmacology , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Mice , Muscle Fibers, Skeletal/cytology , Muscle Fibers, Skeletal/metabolism , Myofibrils/metabolism , Proteasome Endopeptidase Complex/genetics , Ubiquitins/genetics
13.
Int J Mol Med ; 16(3): 471-6, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16077957

ABSTRACT

Incubation of rat isolated skeletal muscles (extensor digitorum longus) in the presence of 100 ng/ml of human recombinant interleukin-15 (IL-15) resulted in a significant decrease in total proteolytic rate, while it had no effect on total protein synthesis as measured by the incorporation of (14)C-phenylalanine into muscle protein. In addition, IL-15 had no effect on either amino acid uptake (as determined by the tissue uptake of labelled [1-(14)C]MeAIB) or alanine utilization by incubated skeletal muscles. Similarly, a single injection of IL-15 (100 microg/kg) in vivo did not result in any changes in amino acid uptake (as measured by the tissue uptake of alpha-[1-(14)C]AIB) or alanine metabolism, with the exception of alanine carbon incorporation into lipids, which was significantly increased in adipose tissue as a result of IL-15 administration. The results suggest that the main mechanism involved in the anabolic effects of IL-15 in skeletal muscle relies on a decrease in the proteolytic rate.


Subject(s)
Interleukin-15/pharmacology , Muscle Proteins/metabolism , Muscle, Skeletal/drug effects , Alanine/metabolism , Aminoisobutyric Acids/pharmacokinetics , Animals , Carbon Radioisotopes , Cell Line , Humans , In Vitro Techniques , Male , Models, Biological , Muscle Fibers, Skeletal/cytology , Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/cytology , Muscle, Skeletal/metabolism , Protein Biosynthesis/drug effects , Rats , Rats, Wistar , Recombinant Proteins/pharmacology
14.
Cancer Res ; 64(18): 6725-31, 2004 Sep 15.
Article in English | MEDLINE | ID: mdl-15374990

ABSTRACT

In cancer cachexia both cardiac and skeletal muscle suffer an important protein mobilization as a result of increased proteolysis. Administration of the beta2-agonist formoterol to both rats and mice bearing highly cachectic tumors resulted in an important reversal of the muscle-wasting process. The anti-wasting effects of the drug were based on both an activation of the rate of protein synthesis and an inhibition of the rate of muscle proteolysis. Northern blot analysis revealed that formoterol treatment resulted in a decrease in the mRNA content of ubiquitin and proteasome subunits in gastrocnemius muscles; this, together with the decreased proteasome activity observed, suggest that the main anti-proteolytic action of the drug may be based on an inhibition of the ATP-ubiquitin-dependent proteolytic system. Interestingly, the beta2-agonist was also able to diminish the increased rate of muscle apoptosis (measured as DNA laddering as well as caspase-3 activity) present in tumor-bearing animals. The present results indicate that formoterol exerted a selective, powerful protective action on heart and skeletal muscle by antagonizing the enhanced protein degradation that characterizes cancer cachexia, and it could be revealed as a potential therapeutic tool in pathologic states wherein muscle protein hypercatabolism is a critical feature such as cancer cachexia or other wasting diseases.


Subject(s)
Adrenergic beta-Agonists/pharmacology , Cachexia/drug therapy , Ethanolamines/pharmacology , Muscle, Skeletal/pathology , Neoplasms, Experimental/metabolism , Animals , Cachexia/metabolism , Cachexia/pathology , Carcinoma, Lewis Lung/metabolism , Carcinoma, Lewis Lung/pathology , Disease Models, Animal , Eating/drug effects , Formoterol Fumarate , Liver Neoplasms, Experimental/metabolism , Liver Neoplasms, Experimental/pathology , Male , Mice , Mice, Inbred C57BL , Muscle Proteins/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Neoplasms, Experimental/pathology , Rats , Rats, Wistar , Sarcoma, Yoshida/metabolism , Sarcoma, Yoshida/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...